NCT06908083View on ClinicalTrials.gov

Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 8, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
HIV
Interventions
OTHER

Analytical Treatment Interruption

Participants will stop their ART (Antiretroviral therapy) on Week 0 and will remain off of their ART for up to 48 weeks or until they meet restart criteria.

Trial Locations (2)

10065

Rockefeller Institute, New York

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH